Tailoring Treatment Intensity in HNSCC: The Expanding Role of Cancer Immunotherapy

October 7, 2025

Webinar Information

Webinar Description

Immunotherapy has become integrated into therapy for many solid tumors. As this new modality has evolved through recurrent/metastatic and recently into the locally advanced setting, new insights and dangers have been encountered, providing insights into complex interactions of conventional modalities with immunotherapeutic modulation of the tumor microenvironment and clinical benefit for patients. The roles of treatment intensification and de-intensification using immunotherapy will be discussed.

Learning Objectives

  • Understand the current status of approved immunotherapeutic agents in HNSCC
  • Recognize the impact of immunotherapy on the tumor microenvironment in treated tumors including the interaction with conventional oncologic therapies
  • Learn the potential roles of treatment intensification and de-intensification using immunotherapy in locally advanced HNSCC

 

Webinar Registration


Take Course

You must have an account and be logged in to register for and to access the course.

Please contact us with any questions at [email protected] or (919) 445–1000.

 

 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 NCPD/CNE
  • 1.00 Participation
Course opens: 
09/23/2025
Course expires: 
10/14/2025
Event starts: 
10/07/2025 - 4:00pm EDT
Event ends: 
10/07/2025 - 5:30pm EDT
Photo of Robert L. Ferris, MD, PhD 

Robert L. Ferris, MD, PhD

Executive Director
UNC Lineberger Comprehensive Cancer Center
Chief of Oncology Clinical Services
UNC Health System
University of North Carolina at Chapel Hill

Disclosures

Activity Directors
This activity has been planned and implemented under the sole supervision of the Course Directors, Jared Weiss, MD; Deborah Marie Stephens, DO; and Kaitlin Morrison, PhD, of the UNC School of Medicine in association with the UNC Office of Continuing Professional Development (CPD). Dr. Weiss is a stockholder in Vesselon, Nuvalent, En Fuego Therapeutics, Vertex, Merus, Revmed; receives consulting fees from AZ, EMD Serono, Nanobiotix, PDS, Amgen, Pharmacosmos, GSK; and receives research grants from Pharmacosmos, Loxo, PDS, Genmab, Iovance, Nurix, TSCAN, Janus, BMS, Summit. These financial relationships have been mitigated. Dr. Stephens has served on advisory boards for Abbvie, AstraZeneca, BeOne, BMS, Genentech, Pfizer, Pharmacyclics, J&J. These were one time consulting efforts, but she is asked periodically to serve on additional boards. She is a consultant for Abbvie and this is an ongoing relationship. She has also received research grants research grants to Lineberger Comprehensive Cancer Center from BeOne, which are ongoing. Dr. Morrison has no relevant financial relationships with ineligible companies as defined by the ACCME. CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME. The planning committee members and their relevant financial relationships with ineligible companies as defined by the ACCME can be found at https://learn.unclcn.org/content/lineberger-cancer-center-grand-rounds-planning-committee.

ACCME
The presenter has no relevant financial relationships with ineligible companies as defined by the ACCME.

ANCC
ANCC: Except as defined above, no one with the ability to control content of this activity has a relevant financial relationship with an ineligible company.

 

Accreditation Statements

1.00 AMA PRA Category 1 Credit™
The School of Medicine of The University of North Carolina at Chapel Hill designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The School of Medicine of the University of North Carolina at Chapel Hill designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

1.00 NCPD/CNE
UNC Health is approved as a provider of nursing continuing professional development by the North Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Criteria for successful completion to claim CE Certificate requires attendance at the NCPD activity, and submission of an evaluation within 7 days.

 

Notice

In most cases, regulations prohibit the repeated use of the same educational activity (Live Webinar or Self-Paced, Online Course but not both) as it relates to satisfying CE requirements to maintain licensure. Attendees are also required to view a minimum of 53 minutes of the live webinar video to receive CE credit. Please contact your individual accreditation agencies for more details.

Altering or submitting modified certificates constitutes fraud that can result in punitive action by the accrediting agency.

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 NCPD/CNE
  • 1.00 Participation
Please login or register to take this course.

 

You must have an account and be logged in to register for and to access the course.

FREE Continuing Education Credit Requirements

 
Camera icon

Use Zoom Link
in the online course

 
  • Attend 53 minutes or more
  • Must be able to see video and slides
  • Joining by Audio-only does not qualify for CE credit
  • Complete online evaluation, select credit, and download certificate

Attendees have 7 days from the webinar air date to complete the online evaluation, select type of continuing education credit, and download a certificate.

See our detailed instructions for more information on attending live webinars and receiving credit.

Please contact us with any questions at [email protected] or (919) 445–1000.